Publication at Third Faculty of Medicine |
2012
Abstract
A case study describes a woman with metastatic melanoma. Due to disease progression during dacarbazine therapy ipilimumab - a fully human monoclonal IgG 1 antibody selectively binding CTLA antigen - was administered.
The complete 12 months lasting remission has been observed in this patient